Default company panoramic image

Kypha, Inc.

Kypha is an early-stage company developing new products to improve the way inflammation and immune activity is monitored and treated.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded September 2009
  • Employees 5

Company Summary

Kypha is currently advancing its lead product, the CompAct™ Test, toward FDA clearance and market launch in 2013. The test uses advanced detection technology and a robust point-of-care format to allow early, accurate detection and real-time monitoring of autoimmune and severe inflammatory disorders. For these patients and their physicians, careful monitoring and early detection are critical to managing disease activity and improving outcomes.


  • Default avatar
    Chad Michael Stiening

    Dr. Stiening is a business development executive with a PhD in life sciences and career focus on technology commercialization. He has studied and worked in the life sciences arena for over 15 years, including academic, large industry and start-up experience. His passion for the "business of science" was realized during his first internship with Monsanto, and evidenced by dual degrees in biology and finance.

  • Default avatar
    Paul Kenneth Olson
    President and CSO

    Dr. Olson was co-founder and CSO of Potentia Pharmaceuticals, which developed the world's first complement inhibitor to treat age-related macular degeneration. The drug was acquired in late 2009 by Alcon and is currently in Phase II clinicals. Prior to his start-up experiences, he held research positions at Harvard and Merck. He's worked closely with several world-renowned thought leaders in immunology, gene delivery and ophthalmology.


  • Default avatar
    Andrew Hoyne (Polsinelli Shughart)
    Default avatar
    Marie Carlie, Linda West (Stone Carlie)

Previous Investors

  • Default avatar
    Default avatar
    Invidiual angel investors (US only)